Search for antihelium in cosmic rays

The Alpha Magnetic Spectrometer (AMS) was flown on the space shuttle Discovery during flight STS-91 in a 51.7 degree orbit at altitudes between 320 and 390 km. A total of 2.86 * 10^6 helium nuclei were observed in the rigidity range 1 to 140 GV. No antihelium nuclei were detected at any rigidity. An upper limit on the flux ratio of antihelium to helium of < 1.1 * 10^-6 is obtained.Comment: 18 pages, Latex, 9 .eps figure

Balloon Measurements of Cosmic Ray Muon Spectra in the Atmosphere along with those of Primary Protons and Helium Nuclei over Mid-Latitude

We report here the measurements of the energy spectra of atmospheric muons and of the cosmic ray primary proton and helium nuclei in a single experiment. These were carried out using the MASS superconducting spectrometer in a balloon flight experiment in 1991. The relevance of these results to the atmospheric neutrino anomaly is emphasized. In particular, this approach allows uncertainties caused by the level of solar modulation, the geomagnetic cut-off of the primaries and possible experimental systematics to be decoupled in the comparison of calculated fluxes of muons to measured muon fluxes. The muon observations cover the momentum and depth ranges of 0.3-40 GeV/c and 5-886 g/cmsquared, respectively. The proton and helium primary measurements cover the rigidity range from 3 to 100 GV, in which both the solar modulation and the geomagnetic cut-off affect the energy spectra at low energies.Comment: 31 pages, including 17 figures, simplified apparatus figure, to appear in Phys. Rev.

Galactic cosmic radiation in the interplanetary space through a modern secular minimum

Recent solar conditions indicate a persistent decline in solar activity—possibly similar to thepast solar grand minima. During such periods of low solar activity, the fluxes of galactic cosmic rays(GCRs) increase remarkably, presenting a hazard for long-term crewed space missions. We used data fromthe Cosmic Ray Telescope for the Effects of Radiation (CRaTER) on the Lunar Reconnaissance Orbiter(LRO) to examine the correlation between the heliospheric magnetic field, solar wind speed, and solarmodulation potential of the GCRs through Cycle 24. We used this correlation to project observations frompast secular solar minima, including the Dalton minimum (1790–1830) and the Gleissberg minimum(1890–1920), into the next cycle. For the case of conditions similar to the Dalton (or Gleissberg) minimum,the heliospheric magnetic field could drop to 3.61 (or 4.06) nT, leading to a dose rate increase of75% (or34%). We showed that accounting for a floor in the modulation potential, invoked by the Badhwar-O'Neill2014 model, moderates the projected radiation levels in Cycle 25. We used these results to determine themost conservative permissible mission duration (PMD,290.4+37.7−35.9and 204.3+26.6−25.2days for 45-year-old maleand female astronauts, respectively) based on a 3% risk of exposure-induced death (REID) at the upper95% confidence interval in interplanetary space

How Friendship Network Characteristics Influence Subjective Well-Being

This article explores how friendship network characteristics influence subjective well-being (SWB). Using data from the 2003 General Social Survey of Canada, three components of the friendship network are differentiated: number of friends, frequency of contact, and heterogeneity of friends. We argue that these characteristics shape SWB through the benefits they bring. Benefits considered are more social trust, less stress, better health, and more social support. Results confirm that higher frequency of contacts and higher number of friends, as well as lower heterogeneity of the friendship network are related to more social trust, less stress, and a better health. Frequency of contact and number of friends, as well as more heterogeneity of the friendship network increase the chance of receiving help from friends. With the exception of receiving help from friends, these benefits are in turn related to higher levels of SWB. Only the frequency of meeting friends face-to-face has a remaining positive direct influence on SWB

2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

Abstract not availableHugh Calkins, Gerhard Hindricks, Riccardo Cappato, Young-Hoon Kim, Eduardo B. Saad … Prashanthan Sanders … et al

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

BACKGROUND: We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. METHODS: In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. FINDINGS: Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50-72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74-1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67-1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74-1·58]; BRII-196 plus BRII-198 1·00 [0·68-1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91-1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88-1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. INTERPRETATION: Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. FUNDING: US National Institutes of Health and Operation Warp Speed

Observations of 14 young open star clusters with the HEGRA system of Cherenkov telescopes

Context. A sample of 14 young open star clusters has been observed in the TeV energy regime with the stereoscopic system of the HEGRA (High Energy Gamma-Ray Astronomy) Cherenkov telescopes from 1997 to 2002, resulting in more than 300 h of observation time. Aims. Young open star clusters may contribute to the acceleration of cosmic rays. The detection of γ-rays (from decaying π0s produced in hadronic interactions) from these objects could be evidence for such a contribution. The results of our observations are compared to available γ-ray data and to a simple hadronic model in the framework of shock front acceleration of cosmic rays in the stellar winds of the cluster members to test the potential of the presently available data on young open star clusters to constrain this type of model. Methods. The stereoscopic system of HEGRA Cherenkov telescopes makes use of the atmospheric imaging technique. Air showers initiated by primary Gamma-Rays are recorded as elliptical images in the telescope cameras. The images from the different telescopes are then superimposed to reconstruct the parameters of the primary particle. This technique (stereoscopy) was pioneered by the HEGRA experiment. Results. No significant excess has been found in the analysed data set of young open star clusters. The derived upper limit on the TeV gamma-ray flux from Berkeley 87 and the available EGRET data from the same direction do not allow us to fully constrain the simple hadronic model used here. The comparison of the upper limits derived for all 14 objects with the flux detected from TeV J2032+4130 (under the assumption of an association of the TeV-signal with the compact stellar association CygOB2) suggests that γ-ray emission from young open star clusters as an object class cannot be ruled out.F. Aharonian, A. Akhperjanian, M. Beilicke, K. Bernlöhr, H.-G. Börst, H. Bojahr, O. Bolz, T. Coarasa, J. L. Contreras, J. Cortina, S. Denninghoff, M. V. Fonseca, M. Girma, N. Götting, G. Heinzelmann, G. Hermann, A. Heusler, W. Hofmann, D. Horns, I. Jung, R. Kankanyan, M. Kestel, A. Konopelko, H. Kornmeyer D. Kranich, H. Lampeitl, M. Lopez, E. Lorenz, F. Lucarelli, O. Mang, H. Meyer, R. Mirzoyan, A. Moralejo, E. Ona-Wilhelmi, M. Panter, A. Plyasheshnikov , G. Pühlhofer, R. de los Reyes, W. Rhode, J. Ripken, G. Rowell, V. Sahakian, M. Samorski, M. Schilling, M. Siems, D. Sobzynska, W. Stamm, M. Tluczykont, V. Vitale, H. J. Völk, C. A. Wiedner, and W. Wittek